Pasireotide (SOM230)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Memorial Sloan Kettering Cancer Center

Conditions

Carcinoid TumorsPancreatic Cancer

Phase 2

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

CompletedNCT00088595

Novartis PharmaceuticalsCarcinoid Tumors

Start: 2004-01-31End: 2008-07-31Updated: 2012-06-04

Phase 3

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

CompletedNCT00994110

Memorial Sloan Kettering Cancer CenterPancreatic Cancer

Start: 2009-10-31End: 2014-09-30Updated: 2016-02-01

Related Papers

Quality of life in RCT of pasireotide to reduce pancreatic complications following resection.

Journal of Clinical Oncology2015-01-20

Pasireotide for Postoperative Pancreatic Fistula

New England Journal of Medicine2014-05-21429 citations

Health-related quality of life (HRQoL) following pancreatic resection in RCT of pasireotide.

Journal of Clinical Oncology2014-05-20